Evidence map›Paper›PMID 39559357›Full record

ArticleFrontiers in immunology2024

Perplexing paradoxical reactions: navigating the complexity of protracted tuberculosis meningitis-a case report.

Megan S Gooding, Dima A Hammoud, Brian Epling, Joseph Rocco, Elizabeth Laidlaw, Safia Kuriakose, Mansi Chaturvedi, Frances Galindo, Stella V Ma, Harry Mystakelis and 7 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Decoding CNS granulomas: cracking the imaging mystery in tuberculosis and neurocysticercosis endemic zones.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Observational
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Megan S GoodingClinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Dima A HammoudCenter for Infectious Disease Imaging, NIH Clinical Center, NIH, Bethesda, MD, United States.
Brian EplingNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Joseph RoccoNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Elizabeth LaidlawNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Safia KuriakoseClinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Mansi ChaturvediDivision of Pulmonary and Critical Care Medicine, University of Maryland, Baltimore, Baltimore, MD, United States.
Frances GalindoNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Stella V MaNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Harry MystakelisNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
April PooleNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Kelly RussoHoward County Department of Health, Columbia, MD, United States.
Maunank ShahDepartment of Health, Baltimore City TB Program, Baltimore, MD, United States.
Joseph L MaloneMontgomery County Department of Health, Silver Spring, MD, United States.
Adam W RupertAIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Irini SeretiNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Maura ManionNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculous meningitis (TBM) has considerable mortality and morbidity, and it often presents therapeutic challenges when complicated by paradoxical reactions (PRs). Here, the clinical course of four cases of TBM patients complicated by PRs in a longitudinal TB cohort is described while also providing insights from the larger clinical cohort. Research flow cytometry, biomarker analysis, and drug concentrations were performed on available samples. All participants were initiated on standard antituberculosis therapy (ATT) and enrolled at the onset of PRs (PR group) or 2-4 months after the start of ATT (controls). The four TBM participants highlighted here presented with fevers, headaches, neurological deficits, and fatigue at the initial presentation. Upon diagnosis, all were initiated on rifampin, isoniazid, pyrazinamide, and ethambutol (RHZE) at standard doses and on corticosteroids. The median time to first PR was 37 days with recrudescence of initial TBM signs and symptoms at the time of PR. At the time of referral, all participants had low drug concentrations requiring dose optimization and regimen intensification as well as recrudescent flares upon corticosteroid taper, with one individual developing enlargement of tuberculoma 1 year following completion of ATT. Based on biomarkers and flow cytometry, PRs are characterized by elevated interferon-gamma and ferritin levels in the plasma compared to controls. In the TBM participants, T-cell activation with elevated levels of inflammatory biomarkers in the cerebrospinal fluid (CSF) was seen at the time of PR. These unique and highly detailed TBM cases provide insights into the pathogenesis of PRs, which may assist with future diagnostics and treatment.

Indexed as

Antitubercular AgentsTuberculosis, MeningealAdultBiomarkersFemaleHumansInterferon-gammaIsoniazidMaleMiddle AgedMycobacterium tuberculosisPyrazinamideAntitubercular AgentsBiomarkersInterferon-gammaIsoniazidPyrazinamidecase seriesimmunocompetentparadoxical reactiontherapeutic drug monitoringtuberculous meningitis

Identifiers

PMID39559357
PMCPMC11570994

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.